Welcome to our dedicated page for Oncolytics Biotech news (Ticker: ONCY), a resource for investors and traders seeking the latest updates and insights on Oncolytics Biotech stock.
Oncolytics Biotech Inc (ONCY) is a clinical-stage biotech company advancing pelareorep, an innovative oncolytic virus immunotherapy targeting multiple cancer types. This dedicated news hub provides investors and researchers with centralized access to corporate developments and scientific progress updates.
Track critical updates including clinical trial results, regulatory milestones, and strategic partnerships. Our curated collection features press releases spanning Phase 2 breast cancer studies, pancreatic cancer research advancements, and manufacturing capacity expansions. Regular updates ensure timely awareness of key developments in HR+/HER2- metastatic breast cancer trials and other high-priority programs.
Discover verified information on pelareorep's mechanism of action, trial design specifics, and intellectual property developments. The resource eliminates the need by aggregating essential updates from randomized controlled studies to manufacturing quality initiatives. Bookmark this page for efficient monitoring of Oncolytics' progress in transforming cancer treatment through viral immunotherapy approaches.
Oncolytics Biotech Inc. (NASDAQ: ONCY) has announced the acceptance of an abstract for an oral presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting, scheduled for June 2-6, 2023 in Chicago, Illinois. The presentation will focus on the BRACELET-1 trial, which evaluates the use of pelareorep in combination with paclitaxel and avelumab for treating metastatic HR+/HER2- breast cancer. Dr. Matt Coffey, CEO, emphasized the significance of this recognition, stating it highlights the trial's importance to oncology stakeholders. The abstract, numbered 1012, will be published on the ASCO website on May 25, 2023. Oncolytics is advancing pelareorep through several clinical trials aimed at enhancing treatment outcomes for various cancers.
Oncolytics Biotech announced that Chief Medical Officer Thomas Heineman will participate in the Viral Immunotherapy – Moving Forward panel at Canaccord Genuity's Horizons in Oncology Virtual Conference on April 20, 2023. The event starts at 9:00 a.m. ET, and a live webcast will be accessible to registered attendees. Company management will also engage in virtual one-on-one investor meetings throughout the conference. Oncolytics is focused on developing pelareorep, an immunotherapeutic agent designed to enhance anti-cancer immune responses for various cancers. The company is advancing clinical trials to evaluate pelareorep in combination with other treatments for conditions like metastatic breast and pancreatic cancer.
Oncolytics Biotech Inc. (NASDAQ: ONCY) will host a conference call and webcast on May 5, 2023, at 8:30 a.m. ET to discuss the first quarter financial results and provide a corporate update. The call can be accessed via toll-free numbers for North America and international callers, and a replay will be available for one week post-event. Oncolytics is developing pelareorep, an immunotherapeutic agent aimed at treating various cancers by inducing anti-cancer immune responses. The company is exploring combinations of pelareorep with checkpoint inhibitors and other oncology treatments, particularly targeting metastatic breast cancer and pancreatic cancer. For further details, visit Oncolytics Biotech's website.
FAQ
What is the current stock price of Oncolytics Biotech (ONCY)?
What is the market cap of Oncolytics Biotech (ONCY)?
